Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | IDH1 | O75874 | 8/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754797 | 0.87 | GAA (0.50) | MAPTTP53TDP1POLBMEN1 | |
| SCHEMBL25754833 | 0.86 | PKM (0.54) | MAPTTP53NPSR1TDP1POLB | |
| SCHEMBL25759510 | 0.83 | MAPT (0.47) | MAPTTP53NPSR1TDP1POLB | |
| SCHEMBL25754798 | 0.83 | EDNRA (0.47) | MAPTTP53NPSR1TDP1POLB | |
| SCHEMBL15647028 | 0.82 | IDH1 (0.66) | MAPTNPSR1TDP1POLBIDH1 | |
| SCHEMBL25754835 | 0.82 | IDH1 (0.53) | MAPTIDH1MEN1KMT2AGAA | |
| SCHEMBL25759512 | 0.82 | MAPT (0.47) | MAPTTP53NPSR1TDP1POLB | |
| SCHEMBL23846522 | 0.81 | POLB (0.60) | MAPTNPSR1TDP1POLBIDH1 | |
| SCHEMBL25754817 | 0.79 | NPSR1 (0.62) | MAPTTP53NPSR1TDP1POLB | |
| SCHEMBL25754831 | 0.79 | MAPT (0.55) | MAPTNPSR1TDP1POLBIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | MAPT 89/4885TP53 13/4885NPSR1 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.